Eisai Announce Japan Launch of Oral Anticoagulant Warfarin Granules 0.2%
Tokyo, Nov 30, 2011 – (JCN Newswire) – Eisai Co., Ltd. announced today that it will launch Warfarin Granules 0.2%, a new formulation of the company’s oral anti-coagulant Warfarin (warfarin potassium), on December 1 in Japan.
Warfarin Granules 0.2% received marketing authorization in Japan on July 15 of this year and was subsequently listed on Japan’s National Health Insurance (NHI) drug price list on November 28. This new formulation is designed to help patients who find it difficult to swallow tablets. It also provides healthcare professionals with the ability to easily micro-adjust the dosage of the medication in accordance with the condition and needs of the patient.
Warfarin is an oral anticoagulant that is used to treat a wide range of indications, with its efficacy having been verified in large-scale overseas clinical studies. The agent is widely prescribed to patients as it is recommended as the standard first-line therapy in the treatment and prevention of thromboembolism such as cardiogenic brain embolism and venous thrombosis in treatment guidelines in Japan, the United States and Europe. However, it is also known to have a narrow therapeutic range and interact with other drugs, making it necessary to adjust dosage accordingly through the monitoring of blood clotting ability by measuring prothrombin time, etc.
Able to be administered to patients who find it difficult to take tablets, such as children or those patients who have trouble swallowing, Warfarin Granules 0.2% allows the ingredient warfarin potassium to be precisely adjusted to less than 0.5 mg, and has been triturated 500-fold to ensure appropriate dose-volume. Furthermore, as light causes warfarin potassium to break down, this new granule formulation has been designed with enhanced photostability, which was achieved by applying a coating to the granules and other measures.
Eisai estimates that there are approximately one million patients currently taking Warfarin in Japan. With the addition of the new granule formulation to its existing line up of Warfarin products, which comprises Warfarin Tablets 0.5 mg, 1 mg and 5 mg, Eisai seeks to make contributions to increase the benefits provided to an ever-greater number of patients.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.co.jp/index-e.html
Public Relations Department Eisai Co. Ltd Tel: +81-(0)3-3817-5120>
Copyright 2011 JCN Newswire. All rights reserved. www.japancorp.net